Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMP-FSGS
NCT06090227Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Dec 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of liquid metformin (Aspargo Labs) in focal segmental glomerulosclerosis (FSGS) (2 arms), sponsored by Yale University. Primary endpoint: Slope of urinary NPHS2:Creatinine ratio at 6 months. Started Dec 2023; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT06090227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06090227.